Glaucoma News and Research

Latest Glaucoma News and Research

Teva announces additional data from QNASL Phase III program on seasonal allergic rhinitis

Teva Pharmaceutical Industries Ltd. announced today that additional data from the Phase III clinical program for QNASL- (beclomethasone dipropionate) Nasal Aerosol will be presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, CA on November 8-13, 2012.

7 Nov 2012

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.

3 Nov 2012

Inotek announces final data from trabodenoson Phase 2 trial on PAOG or ocular hypertension

Inotek Pharmaceuticals Corp., a leader in the development of innovative drug candidates to address significant diseases of the eye, today announced that final data from a Phase 2 clinical trial of trabodenoson, also known as INO-8875, in patients with primary open-angle glaucoma or ocular hypertension will be presented at the Ophthalmology Innovation Summit on Thursday, November 8, 2012 at the Chicago Marriott Downtown Magnificent Mile in Chicago, IL.

2 Nov 2012

New research report shows how bimatoprost causes human hair to regrow

If you're balding and want your hair to grow back, then here is some good news. A new research report appearing online in The FASEB Journal shows how the FDA-approved glaucoma drug, bimatoprost, causes human hair to regrow.

29 Oct 2012

Grp94 chaperone protein can interfere with clearance of myocilin from cells

The chaperone protein Grp94 can interfere with the clearance of another protein known to cause the glaucoma when mutated, a new study led by researchers at the University of South Florida has found. Using a cell model, the researchers also demonstrated that a new specific inhibitor of Grp94 facilitates clearance of the genetically-defective protein, called myocilin, from cells.

10 Oct 2012

Heavy caffeinated coffee consumption may increase risk of exfoliation glaucoma

A new study suggests caffeinated coffee drinkers should limit their intake to reduce their chances of developing vision loss or blindness. According to a scientific paper in Investigative Ophthalmology & Visual Science, heavy caffeinated coffee consumption is associated with an increased risk of developing exfoliation glaucoma, the leading cause of secondary glaucoma worldwide.

4 Oct 2012

Statins linked to reduced glaucoma risk

Cholesterol-lowering medications in the statin class could significantly reduce the risk for developing open-angle glaucoma, show data for more than 500,000 older-age US individuals with hyperlipidemia.

2 Oct 2012

Statins may protect against glaucoma

People who take statins to reduce their risk of cardiovascular disease are less likely to be diagnosed with the most common form of glaucoma, according to a nationwide study of more than 300,000 patients.

2 Oct 2012

Amakem commences AMA0076 Phase 2a study in glaucoma and ocular hypertension

Amakem NV, a kinase platform company focusing on ophthalmology, today announces that it has initiated a Phase 2a proof of concept study of its novel Rho Kinase (ROCK) inhibitor, AMA0076, in patients with glaucoma and ocular hypertension.

27 Sep 2012

Cost of glaucoma revealed

The first 6 months after an open-angle glaucoma diagnosis are the most costly within the first 2 years of having the condition, report US researchers.

26 Sep 2012

Universitat de València to use optical technology to prevent myopia

The Universitat de València will use optical technology in order to prevent myopia, which is considered the most common eye disease in the world. Until now, this technology was only used in astronomy to study images of the Universe.

26 Sep 2012

pSivida reports revenues of $699,000 for fourth quarter 2012

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its fourth quarter and fiscal year ended June 30, 2012.

25 Sep 2012

Structure and function combined is best for detecting, discriminating glaucoma

An index that combines structure and function measurements can detect perimetric and preperimetric glaucoma more accurately, and can differentiate early, moderate, and advanced disease more successfully than systems that consider either variable alone, report researchers.

21 Sep 2012

Weill Cornell to purchase innovative equipment to help detect and treat diabetic retinopathy

Weill Cornell Medical College's ophthalmology services for diabetic patients received a boost last month, courtesy of a grant from the New York City Council secured by Councilwoman Jessica Lappin.

21 Sep 2012

Mathematical modeling can help treat several diseases

Mathematical modeling being tested by researchers at the School of Science at Indiana University-Purdue University Indianapolis (IUPUI) and the IU School of Medicine has the potential to impact the knowledge and treatment of several diseases that continue to challenge scientists across the world.

21 Sep 2012

FDA approves Acton’s AEROSPAN sNDA to treat asthma

Acton Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the sNDA (Supplemental New Drug Application) for AEROSPAN (flunisolide HFA, 80 mcg) Inhalation Aerosol, a hydrofluoroalkane (HFA) orally inhaled corticosteroid indicated for the maintenance treatment of asthma as a prophylactic therapy in adult and pediatric patients 6 years of age and older.

21 Sep 2012

Small subset of patients with OAG accounts for large proportion of all glaucoma-related charges

A small subset of patients with open-angle glaucoma (OAG) account for a large proportion of all glaucoma-related charges in the United States, according to new data published by researchers at the University of Michigan Kellogg Eye Center and Washington University, St. Louis.

20 Sep 2012

Multiple interventions improve medication adherence for patients with chronic conditions

Although patients with chronic conditions who do not take medications as prescribed tend to have poorer health outcomes and higher health care costs than those who adhere to medication regimens, a new report sheds light on the potential for multiple interventions to improve medication adherence.

13 Sep 2012

Readily available index provides practical landmarks for glaucoma patients

The mean deviation index, a widely understood metric for summarizing damage to an individuals’ visual field, could help physicians estimate practical landmarks in patients with glaucoma such as fitness to drive, report UK researchers.

12 Sep 2012

Joslin Diabetes Center, Mass. Eye and Ear partner to form clinical and research alliance

Massachusetts Eye and Ear and the Joslin Diabetes Center announced today that they have reached agreement to form a clinical and research alliance, aimed toward providing coordinated high quality care to eye patients throughout greater Boston, especially those with or at-risk for diabetes-related eye disease.

11 Sep 2012